- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03098186
TXT2HEART COLOMBIA: Evaluation of the Efficacy and Safety of Text Messages to Improve Adherence to Cardiovascular Medications in Secondary Prevention
Purpose of the trial: To evaluate the efficacy and safety of an intervention with SMS messages delivered by mobiles phones to improve adherence to cardiovascular medications in patients with atherosclerotic cardiovascular disease (ASCVD).
Trial design: Two-parallel arm, single-blind, individually randomized controlled trial.
Primary endpoint: Differences in changes (baseline minus 12 months) of: Low density lipoprotein cholesterol (LDL-C), Systolic Blood pressure and Heart Rate.
Secondary endpoints: Differences in the changes (baseline minus 12-months) of: (i) adherence to cardiovascular medications used in secondary prevention measured by MARS-5 questionnaire; and (ii) Urinary levels of 11 dh-TxB2, Rates of composite end-point of cardiovascular death and hospitalization due to cardiovascular disease up to 12 months, Rates of composite of non-cardiovascular death or hospitalizations due to non-cardiovascular disease up to 12 months and Adverse events: traffic accidents and injuries while reading SMS related to the trial.
Duration of follow-up: 12 months
Trial treatment:
Intervention: The active treatment will consist of SMS that are aimed to modified behavioral factors associated with poor adherence to cardiovascular medications used in secondary prevention. The SMS will be delivered daily during the first month, increasing one day of interval for each week during the second month, and weekly thereafter until end of month 12th. In addition, they will receive SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details. The frequency of this SMS will be monthly.
Control: participants will only receive the SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details. The frequency of this SMS will be monthly.
Expected sample size, enrollment and expected number of centers:
Sample size = 1600 Recruitment start date: March , 2017 Recruitment end date: September, 2017 Follow-up end date: March, 2018 Number of centers: 1
Statistical considerations:
- Intention to treat analysis
- The trial has >90% power (2 sided alpha= 0.05) to detect a reduction in LDL-C as low as 5.1 mg/dl, under the assumption that SMS will increase adherence to statins by 7%.
- The primary outcomes will be analyzed using ANCOVA.
Partially Financed by COLCIENCIAS Code: 656672553352
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Santander
-
Floridablanca, Santander, Colombie, 683071
- Fundacion Cardiovascular de Colombia
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age ≥18 years old
History of at least one of the following arterial occlusive events:
- acute coronary syndrome (unstable angina, acute myocardial infarction with or without ST elevation),
- stable angina,
- ischemic cerebrovascular disease,
- peripheral arterial disease or
- coronary revascularization (coronary artery bypass surgery (CABG) or percutaneous transluminal coronary angioplasty (PTCA).
- Own at least one mobile phone
- Ability to read and understand text messages (SMS)
- Intention to stay in the country of recruitment during the next 12 months
Exclusion Criteria:
- Contraindication to take all cardiovascular medications used in secondary prevention.
- Participation in another randomized clinical trial that could interfere with adherence to treatment.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Comparateur actif: Intervention SMS
|
The active treatment will consist of SMS that are aimed to modified behavioral factors associated with poor adherence to cardiovascular medications used in secondary prevention.
The SMS will be delivered daily during the first month, increasing one day of interval for each week during the second month , and weekly thereafter until end of month 12th.
In addition, they will receive SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details.
The frequency of this SMS will be monthly.
|
Comparateur placebo: Control SMS
SMS to thanks for participation in the trial and reminders of trial appointments.
|
Participants will only receive the SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details.
The frequency of this SMS will be monthly.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Differences in physiological variables depending on taking medications: low density lipoprotein cholesterol
Délai: Baseline and 12 months
|
Low density lipoprotein cholesterol (LDL-C) mg/dl
|
Baseline and 12 months
|
Differences in physiological variables depending on taking medications: Systolic Blood pressure
Délai: Baseline and 12 months
|
Systolic Blood pressure mmHg
|
Baseline and 12 months
|
Differences in physiological variables depending on taking medications: Heart Rate
Délai: Baseline and 12 months
|
Heart Rate: Heartbeats per minute
|
Baseline and 12 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Changes in self-reported adherence and recurrence of new cardiovascular and adverse events.
Délai: Baseline and 12 months
|
Adherence to cardiovascular medications used in secondary prevention measured by MARS-5 questionnaire
|
Baseline and 12 months
|
Urinary levels of 11 dh-TxB2
Délai: Baseline and 12 months
|
Changes in Urinary levels of 11 dh-TxB2 pg/dl
|
Baseline and 12 months
|
Death due to cardiovascular disease
Délai: Baseline and 12 months
|
Rate of death due to cardiovascular disease.
|
Baseline and 12 months
|
Hospitalization due to cardiovascular disease
Délai: Baseline and 12 months
|
Rate of hospitalization due to cardiovascular disease.
|
Baseline and 12 months
|
Death due to non-cardiovascular disease
Délai: Baseline and 12 months
|
Rate of death due to non-cardiovascular disease.
|
Baseline and 12 months
|
Hospitalization due to non-cardiovascular disease
Délai: Baseline and 12 months
|
Rate of hospitalizations due to non-cardiovascular disease.
|
Baseline and 12 months
|
Adverse events
Délai: Baseline and 12 months
|
Traffic accidents and injuries while reading SMS related to the trial.
(Percentage)
|
Baseline and 12 months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chaise d'étude: Juan P Casas, PhD, University College, London
- Chaise d'étude: Pablo A Perel, PhD, London School of Hygiene and Tropical Medicine
- Directeur d'études: Norma C Serrano, MsC, Fundacion Cardiovascular de Colombia
- Chercheur principal: Anderson Bermon, MsC, Fundacion Cardiovascular de Colombia
- Chercheur principal: Ana F Uribe, PhD, Universidad Pontificia Bolivariana
Publications et liens utiles
Publications générales
- Bermon A, Uribe AF, Perez-Rivero PF, Prieto-Merino D, Saaibi JF, Silva FA, Canon DI, Castillo-Gonzalez KM, Caceres-Rivera DI, Guio E, Meneses-Castillo KJ, Castillo-Meza A, Atkins L, Horne R, Murray E, Serrano NC, Free C, Casas JP, Perel P. Efficacy and Safety of Text Messages Targeting Adherence to Cardiovascular Medications in Secondary Prevention: TXT2HEART Colombia Randomized Controlled Trial. JMIR Mhealth Uhealth. 2021 Jul 28;9(7):e25548. doi: 10.2196/25548.
- Bermon A, Uribe-Rodriguez AF, Perez-Rivero PF, Prieto-Merino D, Caceres Rivera DI, Guio E, Atkins L, Horne R, Murray E, Serrano Diaz NC, Free C, Perel P, Casas JP. Evaluation of the efficacy and safety of text messages targeting adherence to cardiovascular medications in secondary prevention: the txt2heart Colombia randomised controlled trial protocol. BMJ Open. 2019 Dec 8;9(12):e028017. doi: 10.1136/bmjopen-2018-028017.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 416
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Intervention SMS
-
Centre for Addiction and Mental HealthCanadian Institutes of Health Research (CIHR); Institute for Clinical Evaluative...RecrutementLa schizophrénie | Spectre de la schizophrénie et autres troubles psychotiques | Trouble schizo-affectif | Trouble bipolaire | Psychose | Troubles schizophréniformes | Psychoses induites par une substance | Épisode psychotique | Premier épisode de psychose | Psychoses affectives | Psychose dépressiveCanada
-
Central South UniversityComplétéAutomutilation non suicidaireChine
-
University of RochesterNational Cancer Institute (NCI)ComplétéCancer du col de l'utérusÉtats-Unis
-
Massachusetts General HospitalComplétéHypertension | Diabète de type 2 | HyperlipémieÉtats-Unis
-
Georgetown UniversityComplétéBronzage intérieurÉtats-Unis
-
Samanta Winck MadrugaInconnueCancer | Effet secondaireBrésil
-
University of PennsylvaniaBenefits Data TrustActif, ne recrute pasDéterminants sociaux de la santéÉtats-Unis
-
Jonsson Comprehensive Cancer CenterRetiréSurvivants du cancer infantileÉtats-Unis
-
University of PennsylvaniaComplétéColoscopie | Adhérence, Patient | La messagerie texteÉtats-Unis
-
University of WashingtonJohn L. Locke Jr. Charitable TrustRésiliéInfarctus du myocarde | Intervention coronarienne percutanée | Chirurgie de pontage coronarien | Angine Chronique Stable | Dispositif d'assistance ventriculaire gauche | Transplantation cardiaque | Insuffisance cardiaque stable chronique | Réparation ou remplacement de valve cardiaqueÉtats-Unis